Azra Borogovac, M.D., M.S.
For Azra Borogovac, M.D., M.S., the patient is the most important part of the medical team. She sees the opportunity to provide care to people with cancer as a privilege. In her mind, there is no one-size-fits-all treatment plan. Rather, she sees each patient as a whole person with their own unique priorities and circumstances that must be considered.
Dr. Borogovac pursued her training as a physician at the University of Massachusetts Medical School, where she also trained as a resident in internal medicine. She was a fellow in hematology/oncology and stem cell transplant and cellular therapy at the University of Oklahoma Health Sciences Center, later adding an M.S. in clinical and translational science there as well. In addition, she also completed a highly competitive yearlong program at the American Society of Hematology Clinical Translational Research Institute.
A researcher seeking to improve treatment for blood cancers and ameliorate side effects, she leads clinical trials into protocols for targeted drugs, cellular therapies and blood stem cell transplants. Before joining City of Hope in 2022, she was an assistant professor of hematology/oncology at the University of Oklahoma’s Stephenson Cancer Center.
Dr. Borogovac is fluent in Bosnian. In her free time, she likes to spend time with her daughter, hike, travel and explore new restaurants.
- 2021, M.S., Clinical and Translational Science, University of Oklahoma Health Sciences Center, Oklahoma City, OK
- 2015, M.D., Clinical/Translational Research Pathway, University of Massachusetts Medical School, Worcester, MA
- 2018-2021, Hematology/Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK
- 2015-2018, Internal Medicine, University of Massachusetts Medical School, Worcester, MA
- 2022-present, Assistant Clinical Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope Orange County Lennar Foundation Center, Irvine, CA
- 2021-present, American Society for Transplantation and Cellular Therapy
- 2018-present, American Society of Hematology
- 2018-present, American Society of Clinical Oncology
- 2021-2022, Clinical Research Training Institute, American Society of Hematology
- 2021, James N. George Award, University of Oklahoma
- 2020-2021, Chief Fellow, Hematology/Oncology, University of Oklahoma
- 2014-2015, Senior Scholars Program, UMASS Medical School
- 2010, Phi Beta Kappa Member, Boston University
- 2010, College Scholars Program, Boston University
- 2008-2010, Undergraduate Research Opportunities Program Award, Boston University
- 2006-2010, College of Arts and Sciences Honors Program, Boston University
- 2006, Thomas M. Menino Scholarship, Boston University
- Borogovac A, Tarasco E, Kremer Hovinga JA, Friedman KD, Asch AS, Vesely SK, Prodan CI, Terrell DR, George JN. Prevalence of Neuropsychiatric Symptoms and Stroke in Patients with Hereditary Thrombotic Thrombocytopenic Purpura. Blood. 2022 May 18. ePub ahead of print. PMID: 35584244.
- Borogovac A, Keruakous AR, Bycko M, Holter Chakrabarti J, Ibrahimi S, Khawandanah MO, Selby GB, Yuen C, Schmidt SA, Autry MT, Al-Juhaishi T, Wieduwilt M, Asch AS. Safety and Feasibility of Outpatient Chimeric Antigen Receptor (CAR) T-Cell Therapy: Experience from a Tertiary Care Center. Bone Marrow Transplantation. 2022 Apr 11:1–3. PMID: 35411106.
- Nusrat S, Borogovac A, George JN, Curtis BR, Reese JA. Drug (Vaccine)-Induced Thrombocytopenia 2021: Diversity of Pathogenesis and Clinical Features. Am J Hematol. 2022 Jan 29. Apr;97(4):E162-E165. PMID: 35092624.
- Al-Juhaishi T, Borogovac A, Ibrahimi S, Wieduwilt M, Ahmed S. Reappraising the Role of Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed and Refractory Hodgkin’s Lymphoma: Recent Advances and Outcomes. Journal of Personalized Medicine. 2022; 12(2):125. PMID: 35207613
- Borogovac A, Reese JA, Gupta S, George JN. Morbidities and mortality in patients with hereditary thrombotic thrombocytopenic purpura. Blood Adv. 2022 Feb 8;6(3):750-759. PMID: 34807988.
- Shikdar S, Borogovac A, Mohamad E, Khawandanah M. COVID19 infection in a patient undergoing treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH) with Ravulizumab. Thromb J. 2021 Oct 21;19(1):75. PMID: 34674707.
- Borogovac A, Sahu KK, Vishwanathan GK, Miron PM, Cerny J. A Case of Acute Myeloid Leukemia Harboring a Rare Three-Way Translocation t(5;7;7) Involving the PDGFRB Gene and Successfully Treated with Imatinib. Cancer Manag Res. 2021 Nov;13:8841-8847. PMID: 34858057
- Siddiqui A, Journeycake J, Borogovac A, George JN. Recognizing and Managing Hereditary and Acquired Thrombotic Thrombocytopenic Purpura in Infants and Children. Pediatric Blood & Cancer 2021 May; e28949. PMID: 33660913
- Kasht R, Borogovac A, George JN. Frequency and Severity of Pregnancy Complications in Women with Hereditary Thrombotic Thrombocytopenic Purpura. Am J Hematol 2020 Nov; 95(11):E316-E318. PMID: 32808675
- Sahu K, Borogovac A, Cerny J. COVID-19 related immune hemolysis and thrombocytopenia. J Med Virol 2020 Feb;93(2):1164-1170. PMID: 32776538
- Borogovac A, Tarasco E, Kremer Hovinga JA, George JN. Hypertension in patients with Hereditary Thrombotic Thrombocytopenic Purpura. eJHaem 2020 Jun 10;1(1):342-343. PMID: 35847717
- Borogovac A, and George JN. Stroke and Myocardial Infarction in Hereditary Thrombotic Thrombocytopenic Purpura: Similarities to Sickle Cell Anemia. Blood Advances 2019 Dec 10;3(23):3973-3976. PMID: 31805189
- Borogovac A, Broude NE. Visualization of induced RNA in single bacterial cells. Methods Mol Biol. 2011;714:189-99. PMID: 21431742
- Valencia-Burton M, Shah A, Sutin J, Borogovac A, McCullough RM, Cantor CR, Meller A, Broude NE. Spatiotemporal patterns and transcription kinetics of induced RNA in single bacterial cells. Proc Natl Acad Sci 2009 Sep 22;106(38):16399-404. Epub 2009 Sep 11. PMID: 19805311.